Developing therapies that target multiple immune pathways
18 Nov 2024
Bi/Multispecifics
- Optimal design for a multispecific TCE - what have we learned and what do we still need to learn?
- How do we improve tumour selectivity of therapeutics? Is there a need for new or better combinations of TAAs?
- How should checkpoint inhibition be addressed with multispecifics - same molecule or separate?
Industry Expert
